https://www.appliedxl.com/news/first-affiliated-hospital-zhejiang-university-school-nct05155189 Biopharma News en 2026-07-23T14:24:59.230Z AstraZeneca's GPC3 CAR-T shows 44% response rate in liver cancer, Nature reports https://www.appliedxl.com/news/johnson-tecvayli-talvey-teclistamab-cqyv-talquetamab-tgvs-nct06208150 Biopharma News en 2026-07-23T12:45:30.961Z J&J's Tecvayli-Talvey combo cuts myeloma progression risk 89% in Phase 3 https://www.appliedxl.com/news/lantern-184-2024-readout-nct05933265-96a8c5 Biopharma News en 2026-07-23T12:25:51.612Z Lantern Pharma's LP-184 hits 45% disease control rate in Phase 1a tumor trial https://www.appliedxl.com/news/felzartamab-antibody-mediated-rejection-amr-kidney-nct05021484 Biopharma News en 2026-07-23T12:15:14.092Z dd-cfDNA guidance cut felzartamab dosing by two-thirds in kidney rejection https://www.appliedxl.com/news/eli-lilly-retatrutide-2026-readout-nct05882045 Biopharma News en 2026-07-23T11:06:46.185Z Lilly's retatrutide cuts weight 22.6% in cardiovascular-disease patients https://www.appliedxl.com/news/eli-lilly-retatrutide-2026-readout-nct05929079 Biopharma News en 2026-07-23T11:05:22.366Z Lilly's retatrutide hits 20.8% weight loss, 1.6% A1C cut in TRIUMPH-2 https://www.appliedxl.com/news/koya-dayspring-2026-readout-nct05507346 Biopharma News en 2026-07-23T10:15:03.621Z Koya's Dayspring beats pneumatic compression in older, phlebolymphedema patients https://www.appliedxl.com/news/koya-dayspring-2026-readout-nct05507346-7565a2 Biopharma News en 2026-07-23T11:24:54.425Z Koya's Dayspring beats pneumatic device in TEAYS lymphedema subgroups https://www.appliedxl.com/news/surabgene-lomparvovec-sura-vec-abbv-rgx-314-wet-age-related-macular Biopharma News en 2026-07-23T00:05:24.556Z AbbVie's ASCENT gene-therapy trial vs. aflibercept in wet AMD nears Q4 2026 data https://www.appliedxl.com/news/hutchmed-hmpl-a830-solid-tumors-trial-nct07718581 Biopharma News en 2026-07-22T15:55:54.145Z Hutchmed registers first-in-human trial of ADC HMPL-A830 in tumors https://www.appliedxl.com/news/eso-t01-myeloma-trial-suspended-nct06691685 Biopharma News en 2026-07-22T15:55:28.510Z AstraZeneca deal halts investigator-led ESO-T01 CAR-T trial for myeloma in China https://www.appliedxl.com/news/nanjing-leads-lbl-024-ep-nec-trial-nct07720193 Biopharma News en 2026-07-22T15:54:56.989Z Nanjing Leads Biolabs starts Phase 3 test of LBL-024 in rare EP-NEC tumors https://www.appliedxl.com/news/pharmaessentia-besremi-myelofibrosis-enrollment-nct06468033 Biopharma News en 2026-07-22T15:45:45.462Z PharmaEssentia closes enrollment in Phase 3 interferon trial for early myelofibrosis https://www.appliedxl.com/news/amoytop-inpegsomatropin-turner-syndrome-nct07614152 Biopharma News en 2026-07-22T15:45:39.545Z Amoytop starts dosing Turner syndrome trial testing pegylated growth hormone https://www.appliedxl.com/news/lei-yunshang-huanghou-zhixie-diwan-ibs-d-phase2-nct07721012 Biopharma News en 2026-07-22T15:45:08.085Z Chinese herbal formula enters Phase 2 test for IBS-D in China https://www.appliedxl.com/news/suncadia-hrs-5965-iga-nephropathy-nct07582133 Biopharma News en 2026-07-22T15:45:01.502Z Chengdu Suncadia opens rollover safety study for HRS-5965 in IgA nephropathy https://www.appliedxl.com/news/akeso-ak146d1-breast-cancer-recruiting-nct07591090 Biopharma News en 2026-07-22T15:39:40.986Z Akeso opens recruiting for AK146D1-AK112 combo in HER2-negative breast cancer https://www.appliedxl.com/news/aston-sci-ast-301-gastric-cancer-timing-nct05771584 Biopharma News en 2026-07-22T15:36:28.600Z Aston Sci pushes AST-301 gastric vaccine readout to February 2027 https://www.appliedxl.com/news/cspc-syh2070-mixed-hyperlipidemia-phase2-nct07695597 Biopharma News en 2026-07-22T15:36:15.529Z CSPC's SYH2070 opens enrollment in a crowded ANGPTL3 lipid-lowering field https://www.appliedxl.com/news/amoytop-inpegsomatropin-growth-hormone-deficiency-nct07551804 Biopharma News en 2026-07-22T15:36:00.128Z Xiamen Amoytop opens dosing in adult growth hormone deficiency PK study https://www.appliedxl.com/news/kanghong-khn939-thyroid-eye-disease-phase3-nct07720635 Biopharma News en 2026-07-22T15:35:57.878Z Kanghong starts Phase 3 test of KHN939 in Chinese thyroid eye disease patients https://www.appliedxl.com/news/zhuhai-united-tul108-phase1-nct07719257 Biopharma News en 2026-07-22T15:35:07.752Z Zhuhai United Labs starts first human trial of TUL108, an injectable https://www.appliedxl.com/news/hubei-bio-hw221043-solid-tumors-nct07719920 Biopharma News en 2026-07-22T15:26:16.845Z Hubei Bio registers fifth KIF18A inhibitor trial to enter the clinic https://www.appliedxl.com/news/hengrui-shr-1139-psoriasis-phase2-nct07719530 Biopharma News en 2026-07-22T15:25:59.634Z Hengrui advances third SHR-1139 psoriasis trial as PASI 100 bar https://www.appliedxl.com/news/shanghai-ark-ak3280-ipf-phase3-nct07719023 Biopharma News en 2026-07-22T15:25:44.690Z Shanghai Ark starts Phase 3 of AK3280 against pirfenidone in IPF https://www.appliedxl.com/news/kanghong-khn939-thyroid-eye-disease-nct07720648 Biopharma News en 2026-07-22T15:25:33.005Z Kanghong registers second Phase 3 for its TED antibody KHN939 in China https://www.appliedxl.com/news/clostrabio-anaerostipes-caccae-clb101-2026-readout-nct07336615 Biopharma News en 2026-07-22T13:25:06.432Z ClostraBio says probiotic CLB101 hit safety goal, but posts no numbers https://www.appliedxl.com/news/ucsf-rb-pdat-2026-readout-nct05110001 Biopharma News en 2026-07-22T12:15:00.978Z UCSF's REAGIR trial misses primary endpoint for Rose Bengal eye therapy https://www.appliedxl.com/news/plozasiran-severe-hypertriglyceridemia-readout-2026-c614e3-nct06347003 Biopharma News en 2026-07-22T11:45:34.875Z Arrowhead's plozasiran cuts triglycerides 79% and pancreatitis events in Phase 3 https://www.appliedxl.com/news/plozasiran-severe-hypertriglyceridemia-readout-2026-nct06347016 Biopharma News en 2026-07-22T11:45:09.865Z Arrowhead's plozasiran cuts triglycerides 81% in Phase 3 SHASTA-4 https://www.appliedxl.com/news/radiopharm-theranostics-rad-204-2026-readout-nct06305962 Biopharma News en 2026-07-22T11:26:07.947Z Radiopharm's RAD204 shows one durable partial response in dose-escalation cohort https://www.appliedxl.com/news/emavusertib-ca-4948-relapsed-refractory-primary-central-nct03328078 Biopharma News en 2026-07-22T11:15:43.917Z Curis's emavusertib shows responses in BTKi-resistant brain lymphoma, no ORR given https://www.appliedxl.com/news/science-prima-2026-readout-nct04676854 Biopharma News en 2026-07-22T10:15:33.961Z Science Corp's PRIMA implant restores reading vision in geographic atrophy trial https://www.appliedxl.com/news/syhx2011-breast-cancer-survival-data Biopharma News en 2026-07-22T19:54:41.927Z SYHX2011 shows longer PFS than albumin-bound paclitaxel in advanced breast cancer https://www.appliedxl.com/news/cansino-dtcp-pertussis-vaccine-readout-nct05951725 Biopharma News en 2026-07-22T20:15:29.471Z CanSino's DTcP vaccine tops older DTaP shot on pertussis antibody response https://www.appliedxl.com/news/deramiocel-duchenne-muscular-dystrophy-dmd-cardiomyopathy-fda Biopharma News en 2026-07-22T00:05:16.902Z Capricor's deramiocel faces Aug. 22 FDA decision after CRL reversal https://www.appliedxl.com/news/hengrui-shr-1905-nasal-polyps-readout-nct05891483 Biopharma News en 2026-07-22T15:25:24.937Z Hengrui's Phase 2 SHR-1905 nasal polyp trial completes, data still ahead https://www.appliedxl.com/news/fazamorexant-ticagrelor-interaction-study-nct06671470 Biopharma News en 2026-07-22T20:45:34.652Z Ticagrelor shows no clinically meaningful interaction with fazamorexant https://www.appliedxl.com/news/dalpiciclib-darvin-breast-cancer-visceral-crisis-nct05431504 Biopharma News en 2026-07-22T20:56:23.438Z Dalpiciclib plus endocrine therapy hits 92.5% six-month survival in visceral crisis https://www.appliedxl.com/news/astrazeneca-eplontersen-alxn2220-attriumph-2026 Biopharma News en 2026-07-21T23:20:48.733Z AstraZeneca pauses enrollment in Phase IIb test of eplontersen plus ALXN2220 combo https://www.appliedxl.com/news/vactosertib-pembrolizumab-colorectal-cancer-readout-nct03724851 Biopharma News en 2026-07-22T20:55:24.311Z Vactosertib-pembrolizumab combination shows activity in liver-metastasis-free colorectal cancer https://www.appliedxl.com/news/telix-tlx591-tx-lutetium-177-177lu-rosopatamab-tetraxetan-nct04786847 Biopharma News en 2026-07-21T21:16:04.194Z Telix's TLX591-Tx posts 8.8-month rPFS in small Phase 1 mCRPC study https://www.appliedxl.com/news/acrivon-acr-2316-2026-data-nct06667141 Biopharma News en 2026-07-21T20:46:40.772Z Acrivon presents early ACR-2316 partial responses in WEE1-resistant tumor types https://www.appliedxl.com/news/barzolvolimab-prurigo-nodularis-pn-readout-2026-nct06366750 Biopharma News en 2026-07-21T20:16:27.302Z Celldex's barzolvolimab fails Phase 2 prurigo nodularis trial despite mast cell wipeout https://www.appliedxl.com/news/enhertu-nsclc-destiny-lung05-final-analysis-nct05246514 Biopharma News en 2026-07-22T21:26:10.308Z T-DXd shows 56.9% response rate in China HER2-mutant lung cancer trial https://www.appliedxl.com/news/n-lorem-foundation-allele-selective-aso-2026-readout-2f34d6 Biopharma News en 2026-07-21T16:55:06.529Z n-Lorem's personalized ASOs curb seizures in two SCN2A children https://www.appliedxl.com/news/n-lorem-foundation-allele-selective-aso-2026-readout-nct06314490 Biopharma News en 2026-07-21T16:34:56.557Z n-Lorem's personalized SCN2A ASO tied to seizure drop in one child https://www.appliedxl.com/news/henlius-hlx43-lung-cancer-recruiting-nct07253142 Biopharma News en 2026-07-21T15:56:39.095Z Henlius starts recruiting HLX43-serplulimab trial in advanced lung cancer https://www.appliedxl.com/news/hengrui-hrs9531-obesity-phase3-2027-nct07670884 Biopharma News en 2026-07-21T15:56:25.235Z Hengrui's oral obesity pill HRS9531 starts a new Phase 3, completion set 2027 https://www.appliedxl.com/news/hengrui-hrs9531-obesity-phase3-trial-nct07670884 Biopharma News en 2026-07-21T15:46:41.629Z Hengrui's oral HRS9531 opens third Phase 3 obesity trial in China https://www.appliedxl.com/news/servier-voranigo-astrocytoma-china-real-world-nct06969352 Biopharma News en 2026-07-21T15:45:25.631Z Servier's China real-world Voranigo study closes enrollment at 62 patients https://www.appliedxl.com/news/hansoh-hs-20136-2-obesity-phase1-nct07716241 Biopharma News en 2026-07-21T15:36:19.771Z Hansoh registers Phase 1 obesity trial for injectable HS-20136-2 https://www.appliedxl.com/news/daiichi-sankyo-valemetostat-solid-tumors-2026-nct06244485 Biopharma News en 2026-07-21T15:35:53.399Z Daiichi Sankyo closes enrollment on valemetostat-ADC combo trial at 98 patients https://www.appliedxl.com/news/ascentage-apg-2449-ovarian-cancer-nct06687070 Biopharma News en 2026-07-21T15:35:15.697Z Ascentage nearly doubles enrollment in APG-2449 ovarian cancer trial https://www.appliedxl.com/news/hrs9531-obesity-phase3-enrollment-nct07670884 Biopharma News en 2026-07-21T15:26:43.921Z Hengrui-linked HRS9531 obesity Phase 3 grows to 675 patients as trial opens enrollment https://www.appliedxl.com/news/abbisko-absk211-solid-tumors-phase-1-nct07718165 Biopharma News en 2026-07-21T15:26:02.981Z Abbisko readies pan-KRAS inhibitor ABSK211 for China Phase 1 in tumors https://www.appliedxl.com/news/ascentage-apg-2449-ovarian-cancer-timing-nct06687070 Biopharma News en 2026-07-21T15:26:00.383Z Ascentage pushes APG-2449 ovarian cancer trial readout to May 2027 https://www.appliedxl.com/news/bioray-brl-101-beta-thalassemia-readout-nct05577312 Biopharma News en 2026-07-21T15:25:59.001Z Bioray closes enrollment in BRL-101 gene-editing trial for beta-thalassemia https://www.appliedxl.com/news/orforglipron-foundayo-obesity-approval Biopharma News en 2026-07-21T19:14:45.854Z Orforglipron's first approval covers obesity, not diabetes, per new milestone review https://www.appliedxl.com/news/satricabtagene-autoleucel-gastric-cancer-approval Biopharma News en 2026-07-21T19:55:03.787Z China approves satricabtagene autoleucel, first CAR T for a tumor https://www.appliedxl.com/news/apatinib-trastuzumab-gastric-cancer Biopharma News en 2026-07-21T20:04:48.116Z Apatinib plus trastuzumab curbs IL-6 signaling in HER2-positive gastric cancer https://www.appliedxl.com/news/boehringer-brigimadlin-biliary-cancer-readout-nct05512377 Biopharma News en 2026-07-21T15:35:54.307Z Boehringer's brigimadlin trial in biliary and pancreatic cancer finishes without posted results https://www.appliedxl.com/news/pulnovo-padn-hf-ph-pulmonary-hypertension-nct05824923 Biopharma News en 2026-07-21T15:25:37.052Z Pulnovo's pulmonary artery denervation trial closes enrollment, no data yet https://www.appliedxl.com/news/salubris-sal0120-ckd-phase2-nct07716618 Biopharma News en 2026-07-21T15:45:17.428Z Salubris starts Phase 2 test of oral SAL0120 for proteinuric kidney disease https://www.appliedxl.com/news/astrazeneca-tozorakimab-copd-luna-design-nct05166889 Biopharma News en 2026-07-21T20:25:19.460Z Tozorakimab's LUNA papers detail AstraZeneca's four-trial Phase 3 COPD program https://www.appliedxl.com/news/revakinagene-taroretcel-mactel-pooled-analysis Biopharma News en 2026-07-21T20:24:54.150Z Pooled data show revakinagene taroretcel slows MacTel type 2 progression over 24 months https://www.appliedxl.com/news/mask-ventilation-anesthesia-induction-study Biopharma News en 2026-07-21T20:34:51.886Z Low-tidal-volume mask ventilation cuts lung inhomogeneity during induction https://www.appliedxl.com/news/qibai-pingfei-copd-nk-cell-trial Biopharma News en 2026-07-21T20:45:27.207Z Qibai Pingfei Capsule tied to fewer COPD flare-ups via NK-cell repair